CelLBxHealth said AdventHealth will use its CelLBxHealth Parsortix circulating tumor cell (CTC) platform in two cancer studies evaluating whether exercise can improve patient outcomes. The ACTION study, funded by NIH, will analyze CTCs in 219 colon cancer patients receiving chemotherapy, while the SUNRISE study is set to start in July for 120 lung and GI patients. AdventHealth will count CTCs and characterize PD-L1 expression to support biomarker and correlative endpoints. CelLBxHealth said CTC monitoring can enable multiomic analysis across DNA, RNA, and proteins, positioning the platform as a more comprehensive alternative to ctDNA-only monitoring. The collaboration underscores how oncology trials increasingly use cellular biomarkers tied to immune signaling and risk stratification, with CTC workflows designed to integrate into standard lab instrumentation.